Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Nestlé to acquire peanut allergy firm Aimmune in $2.6 billion deal
by Ryan Cross
September 3, 2020
| A version of this story appeared in
Volume 98, Issue 34
Nestlé plans to acquire Aimmune Therapeutics, which recently won US Food and Drug Administration approval of Palforzia, the first treatment designed to reduce allergic reactions to peanuts. Nestlé has invested about $470 million in Aimmune since 2016. The Swiss firm will now buy the rest of Aimmune in a deal valuing it at $2.6 billion. Aimmune previously predicted that peak annual sales of Palforzia could top $1 billion.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X